Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

Sanchez C, Asin KE, Artigas F.

Pharmacol Ther. 2015 Jan;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001. Epub 2014 Jul 9. Review.

2.

New applications of disease genetics and pharmacogenetics to drug development.

Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK.

Curr Opin Pharmacol. 2014 Feb;14:81-9. doi: 10.1016/j.coph.2013.12.002. Epub 2014 Jan 3. Review.

3.

Effects of haloperidol and clozapine on Fos expression in the primate striatum.

Wirtshafter D, Asin KE.

Neuroreport. 2003 Dec 19;14(18):2429-32.

PMID:
14663205
5.
6.
7.
8.

Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.

Michaelides MR, Hong Y, DiDomenico S Jr, Bayburt EK, Asin KE, Britton DR, Lin CW, Shiosaki K.

J Med Chem. 1997 May 23;40(11):1585-99.

PMID:
9171869
9.
10.

Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.

Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C.

Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90.

PMID:
8997599
11.
12.

Amphetamine induces Fos-like immunoreactivity in the striatum of primates.

Asin KE, Wirtshafter D, Nikkel A.

Brain Res. 1996 May 6;719(1-2):138-42.

PMID:
8782873
13.

Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.

Lin CW, Bianchi BR, Miller TR, Stashko MA, Wang SS, Curzon P, Bednarz L, Asin KE, Britton DR.

J Pharmacol Exp Ther. 1996 Mar;276(3):1022-9.

PMID:
8786531
14.

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.

J Pharmacol Exp Ther. 1996 Jan;276(1):150-60.

PMID:
8558425
16.

Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.

Asin KE, Bednarz L, Nikkel A, Perner R.

J Pharmacol Exp Ther. 1995 Jun;273(3):1483-90.

PMID:
7791123
17.
18.

CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.

Bennett MJ, Nikkel AL, Bianchi BR, Miller TR, Bednarz L, Witte DG, Stashko M, Wang SS, Gore PA, Asin KE, et al.

J Med Chem. 1994 May 27;37(11):1569-71.

PMID:
8201591
19.

Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.

Holladay MW, Kopecka H, Miller TR, Bednarz L, Nikkel AL, Bianchi BR, Witte DG, Shiosaki K, Lin CW, Asin KE, et al.

J Med Chem. 1994 Mar 4;37(5):630-5.

PMID:
8126703
20.

Repeated D1 receptor agonist treatment blocks cocaine-induced locomotor activity and c-fos expression.

Asin KE, Nikkel AL, Wirtshafter D.

Brain Res. 1994 Feb 21;637(1-2):342-4.

PMID:
7910104
21.

Dopamine agonists and stress produce different patterns of Fos-like immunoreactivity in the lateral habenula.

Wirtshafter D, Asin KE, Pitzer MR.

Brain Res. 1994 Jan 7;633(1-2):21-6.

PMID:
8137158
23.

Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression.

Asin KE, Wirtshafter D.

Eur J Pharmacol. 1993 Apr 22;235(1):167-8.

PMID:
8100194
24.

A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey.

Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Nadzan AM.

Pharmacol Biochem Behav. 1992 Aug;42(4):699-704.

PMID:
1513850
25.

Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.

Holladay MW, Bennett MJ, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L, et al.

J Med Chem. 1992 Aug 7;35(16):2919-28.

PMID:
1501220
26.

Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide.

Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Montana WE, Cullen MJ, Shiosaki K, Craig R, Nadzan AM.

Am J Physiol. 1992 Jul;263(1 Pt 2):R125-35.

PMID:
1636779
27.

Differential effects of CCK-JMV-180 on food intake in rats and mice.

Asin KE, Bednarz L.

Pharmacol Biochem Behav. 1992 Jun;42(2):291-5.

PMID:
1631182
28.

A68930: a potent agonist specific for the dopamine D1 receptor.

Kebabian JW, DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE.

Neurochem Int. 1992 Mar;20 Suppl:157S-160S.

PMID:
1365416
29.

Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats.

Asin KE, Gore PA Jr, Bednarz L, Holladay M, Nadzan AM.

Brain Res. 1992 Jan 31;571(1):169-74.

PMID:
1611492
30.

Differential effects of serotonergic and catecholaminergic drugs on ingestive behavior.

Asin KE, Davis JD, Bednarz L.

Psychopharmacology (Berl). 1992;109(4):415-21.

PMID:
1365856
31.

Dissociation of haloperidol-induced "anhedonia" and catalepsy by lesions of the dorsal raphe nucleus.

Wirtshafter D, Asin KE.

Pharmacol Biochem Behav. 1991 Dec;40(4):1001-4.

PMID:
1816554
32.

Synthesis and dopaminergic activity of 3-substituted 1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyrans: characterization of an auxiliary binding region in the D1 receptor.

DeNinno MP, Schoenleber R, Perner RJ, Lijewski L, Asin KE, Britton DR, MacKenzie R, Kebabian JW.

J Med Chem. 1991 Aug;34(8):2561-9.

PMID:
1652023
33.

A68930: a potent agonist selective for the dopamine D1 receptor.

DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, et al.

Eur J Pharmacol. 1991 Jun 25;199(2):209-19.

PMID:
1683288
34.

(1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist.

DeNinno MP, Schoenleber R, Asin KE, MacKenzie R, Kebabian JW.

J Med Chem. 1990 Nov;33(11):2948-50. No abstract available.

PMID:
1977907
35.
36.

Evidence for dopamine involvement in reinforcement obtained using a latent extinction paradigm.

Asin KE, Wirtshafter D.

Pharmacol Biochem Behav. 1990 Jun;36(2):417-20.

PMID:
2356217
37.
38.

A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.

Kerkman DJ, Ackerman M, Artman LD, MacKenzie RG, Johnson MC, Bednarz L, Montana W, Asin KE, Stampfli H, Kebabian JW.

Eur J Pharmacol. 1989 Aug 3;166(3):481-91.

PMID:
2509217
39.

Studies on D1 and D2 dopamine receptor involvement in conditioned taste aversions.

Asin KE, Montana WE.

Pharmacol Biochem Behav. 1989 Apr;32(4):1033-41.

PMID:
2572001
40.

Is dopamine involved in the hyperactivity produced by injections of muscimol into the median raphe nucleus?

Wirtshafter D, Klitenick MA, Asin KE.

Pharmacol Biochem Behav. 1988 Jul;30(3):577-83.

PMID:
3211966
41.
42.
43.

Evidence against serotonin involvement in the hyperactivity produced by injections of muscimol into the median raphe nucleus.

Wirtshafter D, Klitenick MA, Asin KE.

Pharmacol Biochem Behav. 1987 May;27(1):45-52.

PMID:
2441421
44.

Serotonin-immunoreactive projections to the hippocampus from the interpeduncular nucleus in the rat.

Wirtshafter D, Asin KE, Lorens SA.

Neurosci Lett. 1986 Mar 14;64(3):259-62.

PMID:
2421209
45.

Behavioral and biochemical studies of the substrates of median raphe lesion induced hyperactivity.

Wirtshafter D, Montana W, Asin KE.

Physiol Behav. 1986;38(6):751-9.

PMID:
3823192
46.
47.
48.
49.

Failure to establish a conditioned place preference with ethanol in rats.

Asin KE, Wirtshafter D, Tabakoff B.

Pharmacol Biochem Behav. 1985 Feb;22(2):169-73.

PMID:
3983210
50.

Pentobarbital-induced drinking does not rely on a renal dipsogen.

Asin KE, Wirtshafter D, Tabakoff B.

Physiol Behav. 1985 Jan;34(1):151-3.

PMID:
4041049

Supplemental Content

Support Center